EASD 2025
15 - 19 September 2025
Semaglutide and risk reduction of major adverse limb events in diabetes: A pooled analysis of 13,975 participants from the SOUL, FLOW and STRIDE randomised trials
Keywords
Get notified when materials for EASD 2025 and future congresses become available:
Get notified when materials for EASD 2025 and future congresses become available:
Success
We will notify you when new materials become available for EASD 2025 and future congresses.
We will keep you updated in your inbox:
Almost Done